Sevoflurane does not inhibit human platelet aggregation induced by thrombin.

Area of Science:

• Anesthesiology
• Hematology
• Cardiovascular Research

Background:

• Sevoflurane is known to inhibit adenosine diphosphate (ADP)-induced platelet aggregation by reducing thromboxane A2.
• Platelet aggregation can be triggered by thrombin, which activates different intracellular signaling pathways, including inositol 1,4,5-triphosphate (IP3) production.
• The study investigates the precise effect of sevoflurane on thrombin-mediated platelet activation.

Purpose of the Study:

• To determine the net effect of sevoflurane on human platelet aggregation induced by thrombin.
• To compare the effects of sevoflurane, halothane, and isoflurane on thrombin-induced platelet responses.
• To elucidate the mechanisms underlying sevoflurane's action on platelet calcium signaling.

Main Methods:

• Washed human platelets were incubated with varying concentrations of sevoflurane, halothane, or isoflurane.
• Platelet aggregation was measured using an aggregometer following stimulation with thrombin.
• Intracellular calcium concentrations and inositol 1,4,5-triphosphate levels were quantified using fluorometry and radioimmunoassay, respectively.

Main Results:

• Halothane significantly inhibited thrombin-induced platelet aggregation and increased intracellular calcium concentration.
• Halothane also suppressed calcium release from the dense tubular system and reduced inositol 1,4,5-triphosphate levels.
• Sevoflurane and isoflurane did not significantly alter platelet aggregation, intracellular calcium levels, or calcium mobilization in response to thrombin.

Conclusions:

• Sevoflurane does not inhibit human platelet aggregation when induced by strong agonists like thrombin.
• The findings contrast with sevoflurane's known inhibitory effects on platelet aggregation induced by weaker agonists (e.g., ADP).
• Sevoflurane's anesthetic action does not appear to impair platelet responsiveness to potent physiological activators.